46. Malignant rheumatoid arthritis
4,183 clinical trials,   2,538 drugs   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03762824
(ClinicalTrials.gov)
June 14, 20163/12/2018Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic DiseaseCombined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response.Rheumatoid Arthritis;Systemic Lupus;Sjögren Syndrome;Systemic Vasculitis;SpondyloarthritisBiological: 13-valent pneumococcal conjugate vaccine;Biological: 23-valent pneumococcal polysaccharide vaccineRegion SkaneNULLActive, not recruiting18 YearsN/AAll300Phase 4NULL
2NCT02547493
(ClinicalTrials.gov)
March 3, 20167/9/2015Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis PatientsComparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With AbataceptRheumatoid ArthritisBiological: pneumococcal polysaccharide vaccine;Biological: pneumococcal conjugate vaccine;Drug: AbataceptUniversity Hospital, MontpellierBristol-Myers SquibbActive, not recruiting18 Years85 YearsAll80N/AFrance;Monaco
3EUCTR2007-006539-29-SE
(EUCTR)
14/03/200820/12/2007Effects of different anti-rheumatic treatments of arthritis on antibody response following pneumococcal vaccination using PrevenarEffects of different anti-rheumatic treatments of arthritis on antibody response following pneumococcal vaccination using Prevenar Patients with rheumatic diseases (rheumatoid arthritis and spondyloarthripaties) who are going to be vaccinated with Prevenar vaccine in order to study the serological responses to two pneumococcal serotypes and to study the impact of different treatment modalities on serological responses.Trade Name: Prevenar vaccine
Product Name: Prevenar vaccine
INN or Proposed INN: 7-valent Pneumococcal Conjugate vaccine
Dept of Rheumatology, Lund University Hospital, Lund, SwedenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
500Sweden